Related Experiment Video
Updated: Sep 20, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer
Hossein Jadvar1, Patrick M Colletti2
1Division of Nuclear Medicine, Department of Radiology, USC Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Abstract:
Hormonal therapy has long been recognized as a mainstay treatment for prostate cancer. New generation imaging agents have provided unprecedented opportunities at all phases along the natural history of prostate cancer. We review the literature on the effect of androgens and androgen deprivation therapy on prostate tumor at its various biological phases using the new generation molecular imaging agents in conjunction with positron emission tomography.
Insights
New imaging agents combined with positron emission tomography reveal how androgens and androgen deprivation therapy impact prostate cancer across all disease stages. This review explores these effects on tumor biology.
Area of Science:
- Oncology
- Radiology
- Endocrinology
Background:
- Hormonal therapy is a primary treatment for prostate cancer.
- Androgen signaling plays a critical role in prostate cancer development and progression.
- Advances in molecular imaging offer new insights into cancer biology.
Purpose of the Study:
- To review the literature on the effects of androgens and androgen deprivation therapy (ADT) on prostate cancer.
- To explore the utility of novel molecular imaging agents in understanding these effects.
- To examine prostate cancer at various biological phases.
Main Methods:
- Literature review of studies utilizing advanced molecular imaging.
- Focus on agents used in conjunction with positron emission tomography (PET).
- Analysis of effects on prostate tumors across different stages of the disease.
Main Results:
- New generation imaging agents provide detailed insights into prostate cancer at all stages.
- Positron emission tomography (PET) aids in visualizing the impact of hormonal manipulation.
- Understanding androgen effects is crucial for optimizing treatment strategies.
Conclusions:
- Molecular imaging, particularly PET, enhances the understanding of androgen's role in prostate cancer.
- These technologies offer opportunities for improved monitoring and treatment of prostate cancer.
- The interplay between hormonal therapy and tumor biology is better elucidated through advanced imaging.
